EVALUATION OF EFFICACY AND SAFETY OF COMPLEX TREATMENT WITH INFLIXIMAB AND METHOTREXATE COMPARING WITH METHOTREXATE MONOTHERAPY OF CHILDREN WITH JUVENILE POLYARTICULAR IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/vsp.v11i2.216
Abstract
In this study the results of the investigation of complex treatment with Infliximab and Methotrexate efficacy and safety of 28 patients
comparing with Methotrexate treatment of 41 patients with polyarticular juvenile idiopathic arthritis at the age of 8–17 years are analyzed. The follow-up period was 1 year. Infliximab was administered according to the following scheme: 0, 2, 6 weeks and then every 8 weeks. The dosage of Infliximab in children with early onset of juvenile idiopathic arthritis was 3,0 mg/kg per infusion. Clinical remission, decrease and normalization of laboratory markers, complete restoration of joints function and improvement of life quality in 57,7% were established after 46 weeks of treatment with Infliximab and Methotrexate comparing with 16% in children treated with Methotrexate monotherapy.
comparing with Methotrexate treatment of 41 patients with polyarticular juvenile idiopathic arthritis at the age of 8–17 years are analyzed. The follow-up period was 1 year. Infliximab was administered according to the following scheme: 0, 2, 6 weeks and then every 8 weeks. The dosage of Infliximab in children with early onset of juvenile idiopathic arthritis was 3,0 mg/kg per infusion. Clinical remission, decrease and normalization of laboratory markers, complete restoration of joints function and improvement of life quality in 57,7% were established after 46 weeks of treatment with Infliximab and Methotrexate comparing with 16% in children treated with Methotrexate monotherapy.
About the Authors
V. A. Kel'tsev
Samara State Medical University
Russian Federation
Vladimir Alekseevich Kel'tsev, PhD, professor, Head of the Department of Theoretical Pediatrics of Samara State Medical University
Russian Federation
Vladimir Alekseevich Kel'tsev, PhD, professor, Head of the Department of Theoretical Pediatrics of Samara State Medical University
L. I. Grebenkina
Samara State Medical University
Russian Federation
Russian Federation
S. A. Pyrkova
Samara State Medical University
Russian Federation
Russian Federation
N. S. Pryanichnikova
Samara State Medical University
Russian Federation
Russian Federation
S. A. Goryunov
Samara State Medical University
Russian Federation
Russian Federation
N. V. Lagoda
Samara State Medical University
Russian Federation
Russian Federation
References
1. Cassidy J., Petty R. et al. Textbook of paediatric rheumatology, 2nd end. New York: Churchill Livigstone. 2002.
2. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: Веди. 2007.
3. Кельцев В. А. Ювенильный идиопатический артрит. Самара: ООО ИПК «Содружество». 2005. 214 с.
4. Кельцев В. А. Клиническая артрология. Руководство для врачей. Самара: ООО ИПК «Содружество». 2008. 616 с.
5. Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294: 1671–1684.
6. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.
7. Schett G. Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity. 2008; 41: 224–229.
8. Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоид- ного артрита. Аутоиммунные заболевания. Москва. 2002. 127 с.
9. EI-Gabalawy H. S., Lipsky R.E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004; 4 (2): 297–301.
10. Foster H. E., Marshall N., MyersA. et at. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003; 48: 767–775.
11. Lomater C., Gerloni V., Gattinara M. et al. Systemic onset juvenile rheumatoid arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.
12. Minden K., Niewerth M., Listing J. et al. Long-term outcome in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2392–2401.
13. Woo R., Wilkinson N. Prieur A. M. et al. Open label phase 2 trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of efficacy of IL-6 receptor blocade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 2005; 7: 1281–1288.
14. Feldman M., Brennan R., Maini R. N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.
15. Насонов Е. Л. Фактор некроза опухоли _ — новая мишень для противовоспалительной терапии ревматоидного артрита. Российский медицинский журнал. 2000; 8 (17).
16. Bradley J. R. TNF-mediated inflammatory disease. J. Pathol. 2008; 214: 149–160.
17. Ackermann C., Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets. 2007; 11: 1369–1384.
18. Smolen J. S., Man C., van der Heijde D. M. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 2009; 68 (6): 823–827.
19. Takeuchi T., Yamanaka H., Inoue E. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: oneyear outcome of joint destruction (RECONFIRM-2J). Mod. Rheumatol. 2008; 18 (5): 447–454.
20. Pavelka K., Gatterova J., Tegzova D. et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. Dm. Exp. Rheumatol. 2007; 25 (4): 540–555.
21. Алексеева Е. И., Бзарова Т. М., Валиева С. И. и др. Влияние инфликсимаба на клинические и лабораторные показате- ли активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7 (2): 22–29.
22. Алексеева Е. И., Алексеева А. М., Валиева С. И. и др. Влияние инфликсимаба на динамику функционального класса и рентгенологические изменения хрящевой и костной ткани суставов у больных с различными вариантами ювенильно- го артрита. Вопросы современной педиатрии. 2008; 7 (4): 30–44.
23. Corona R, Scarazatti M., Dell'erra L. et al. Active refractory juvenile idiopathic arthritis: treatment with infliximab. Efficacy and safety. Ital. J. Pediatr. 2004; 30: 165–168.
24. Mangge H., Heinzl B., Grubbauer H. M. et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol. Int. 2003; 23: 258–261.
25. Steinbrocker О., Traeger C. H., Batterman R. C. Therapeuticcriteria in rheumatoid arthritis. J. Am. Med. Assoc. 1949; 140: 659–662.
Review
For citations:
Kel'tsev V.A., Grebenkina L.I., Pyrkova S.A., Pryanichnikova N.S., Goryunov S.A., Lagoda N.V. EVALUATION OF EFFICACY AND SAFETY OF COMPLEX TREATMENT WITH INFLIXIMAB AND METHOTREXATE COMPARING WITH METHOTREXATE MONOTHERAPY OF CHILDREN WITH JUVENILE POLYARTICULAR IDIOPATHIC ARTHRITIS. Current Pediatrics. 2012;11(2):82-89. (In Russ.) https://doi.org/10.15690/vsp.v11i2.216
Views:
841
Email this article 
